Helene Campbell, the 21-year-old Ottawa woman recovering from a double-lung transplant, is back in hospital after experiencing shortness of breath.
Research and Markets: 6th Asian Pacific Congress of Heart Failure (APCHF … – SunHerald.com
Research and Markets: 6th Asian Pacific Congress of Heart Failure (APCHF …SunHerald.comDUBLIN — Research and Markets (http://www.researchandmarkets.com/research/7h3s6h/6th_asian_pacific) has announced the addition of GlobalData 's new report &qu…
Novartis to probe Indian drug approval allegations – Economic Times
IBNLive.comNovartis to probe Indian drug approval allegationsEconomic TimesIn the case of 11, including Novartis' everolimus and aliskiren, it found that "mandatory" Phase III trials – the final stage of testing before a drug is approved …
Double-lung transplant Helene Campbell back in hospital
TORONTO – Helene Campbell, the 21-year-old Ottawa woman recovering from a double-lung transplant, is back in Toronto General Hospital after experiencing shortness of breath.
Weighing the pros and cons of cortisone shots – Chicago Tribune
Weighing the pros and cons of cortisone shotsChicago TribuneThe corticosteroids are powerful anti-inflammatories that can relieve pain, but the side effects are a drawback. As pills, they deplete bone and have other systemic effects. Injected cortisone…
ASK THE EXPERT: Low sodium diet needed for heart failure patients – Muncie Star Press
ASK THE EXPERT: Low sodium diet needed for heart failure patientsMuncie Star PressMore than 5.5 million people in the United States have a medical diagnosis of heart failure. With the direct and indirect cost of heart failure estimated at $37 billion i…
Boy to travel to US to have heart transplant surgery – Mainichi Daily News
Boy to travel to US to have heart transplant surgeryMainichi Daily NewsTOKYO (Kyodo) — A 13-year-old Japanese boy suffering from serious dilated cardiomyopathy will travel to the United States on Thursday to have a heart transplant surgery, members of…
New Drug Shows Promise for Myeloma Patients
WEDNESDAY, May 9 (HealthDay News) — Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem cell transplant or gett…
Lenalidomide shows significant benefit for myeloma patients, phase III study suggests
Medical researchers report significant time-to-progression benefit as well as survival benefit for patients who took maintenance doses of lenalidomide following stem-cell transplant.
Gene-modified stem cell transplant protects patients from toxic side effects of chemotherapy, study suggests
For the first time, scientists have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of chemotherapy. Initial results of the ongoing, small clinical trial of…